Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization.
Ontology highlight
ABSTRACT: Prescription of PCSK9-inhibitors has increased in recent years but not much is known about its off-target effects. PCSK9-expression is evident in non-hepatic tissues, notably the brain, and genetic variation in the PCSK9 locus has recently been shown to be associated with mood disorder-related traits. We investigated whether PCSK9 inhibition, proxied by a genetic reduction in expression of PCSK9 mRNA, might have a causal adverse effect on mood disorder-related traits. We used genetic variants in the PCSK9 locus associated with reduced PCSK9 expression (eQTLs) in the European population from GTEx v8 and examined the effect on PCSK9 protein levels and three mood disorder-related traits (major depressive disorder, mood instability, and neuroticism), using summary statistics from the largest E
SUBMITTER: Aman A
PROVIDER: S-EPMC9799310 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA